Furthermore, the administration of PRMT3 inhibitor, SGC707, disrupted the increased ADMA modification mediated by PRMT3, and abolished PRMT3‐induced HCC glycolysis and tumour growth. Here, PRMT3 is linked to hepatocellular carcinoma.